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Prevention of Acute Allograft Rejection
by Antibody Targeting of TIRC7,
a Novel T Cell Membrane Protein
et al., 1996; Crabtree, 1989). The T cell response is initi-
ated by the interaction of the antigen-specific T cell recep-
tor (TCR) with peptide presented by major histocom-
patibility complex (MHC) molecules on the surface of
antigen-presenting cells (APCs). Additional signals are
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The present study was conducted in order to identifySummary
novel transcripts that are induced early after T cell stimu-
lation with alloantigen, as products of such transcriptsA novel 75 kDa membrane protein, TIRC7, is described
are likely to play an important role in the activation pro-that exhibits a central role in T cell activation in vitro
cess or its regulation and might be targets for specificand in vivo. Modulation of TIRC7-mediated signals
modulation. We describe a differentially expressed Twith specific anti-TIRC7 antibodies in vitro efficiently
cell mRNA, termed TIRC7, that is transiently upregulatedprevents human T cell proliferation and IL-2 secretion.
in early T cell stimulation with alloantigen. The transcriptMoreover, anti-TIRC7 antibodies specifically inhibit
encodes a membrane protein that plays an essentialtype 1 subset specific IFN-g expression but spare the
role in T cell activation. The biological significance oftype 2 cytokine IL-4. Diminished proliferation but not
the protein is underscored by the fact that targeting ofIFN-g secretion is reversible by exogenous rIL-2. An
TIRC7 with specific antibodies significantly prolongs ratanti-TIRC7 antibody that cross-reacts with the 75 kDa
kidney allograft survival. Therefore, TIRC7 may serverat homolog exhibits inhibition of rat alloimmune re-
as a target for in vivo modulation of cellular immunesponse in vitro and significantly prolongs kidney allo-
response in the context of organ transplantation andgraft survival in vivo. Targeting of TIRC7 may provide
autoimmune diseases.a novel therapeutic approach for modulation of the
immune response.
Results
Introduction
TIRC7 Is Differentially Expressed in Alloactivated
Human T Cells and Encodes a NovelT cell activation is a serial process involving multiple
Membrane Proteinsignaling pathways and sequential changes in gene ex-
To identify novel genes induced during the early stagespression resulting in differentiation of T cells into distinct
of T cell activation in response to alloantigens, differen-subpopulations, i.e., Th1 and Th2, which are distinguish-
tial display RT-PCR analysis of mRNA expression wasable by their pattern of cytokine production and charac-
performed at time 0 and 24 hr after initiation of a humanterize the mode of the cellular immune response (Abbas
mixed lymphocyte culture (MLR). As shown in Figure
1A, a 350 bp cDNA fragment was identified that was
induced at 24 hr after stimulation, and was used to# To whom correspondence should be addressed (e-mail: nalan.
utku@charite.de). identify several clones from l-gt-10 cDNA libraries from
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Figure 1. Identification of TIRC7 from Alloactivated T Cells
(A) Differential display identification of a 350 bp transcript upregulated 24 hr after alloactivation of human T lymphocytes. Each lane shows
an mRNA expression pattern from a one-way MLR at either 0 or 24 hr after activation. Two different MLRs (a and b) exhibited similar patterns
of gene expression.
(B) Nucleotide sequence of TIRC7 cDNA. The cDNA and deduced 614 amino acid sequences of the TIRC7 transcript are shown. Predicted
transmembrane regions are underlined and bold.
(C) The predicted secondary structure of TIRC7 protein contains seven transmembrane spanning domains (TM). Peptides (P1±P7) synthesized
according to sequences in the putative intracellular amino terminus (NH3), extracellular carboxy terminus (COOH), and the largest intracellular
(IC) and extracellular (EC) loop were used to raise rabbit anti-TIRC7 polyclonal antibodies. Anti-TIRC7 antibodies with immune modulatory
effects are given in the box.
human T cells. Sequence analysis revealed a 2488 bp with any proteins known to be involved in T cell activa-
tion. TIRC7 does share amino acid homology (12%±cDNA that was designated as TIRC7 (T cell immune re-
sponse cDNA 7; GenBank accession number: AF025374), 71%) with several proteins reported as putative subunits
of the vacuolar proton pump H1-ATPase (VPP) in a vari-containing an open reading frame of 1842 nt and pre-
dicting a protein length of 614 amino acids (Figure 1B). ety of species (Bowman et al., 1988; Lee et al., 1990;
Perin et al., 1991; Manolson et al., 1992, 1994; Peng et al.,Hydrophobicity analysis of the protein sequence re-
vealed seven hydrophobic domains, compatible with 1994; Solioz and Davies, 1994; Li et al., 1996). Analysis
of the complete genomic DNA organization of TIRC7transmembrane spanning domains. The N terminus of
TIRC7 lacks a consensus signal peptide sequence and, revealed that TIRC7 and a recently reported human
cDNA, named OC116 (Li et al., 1996), are alternativelyas it is followed by seven hydrophobic domains, the
protein has a predicted topology of an intracellular N spliced transcripts of the same gene (data not shown).
The function of OC116 is so far unknown and the 2640terminus and extracellularly oriented C domain (Figure
1C). TIRC7 contains multiple putative sites of posttrans- nt mRNA, encoding an 829-residue protein, was demon-
strated to be exclusively expressed in human osteo-lational modification including phosphorylation sites for
PKC (at amino acids 58, 98, and 148) and PKA (at amino clastoma cells. The regions of strongest homology be-
tween TIRC7 and these putative VPPs are predominantlyacid 21), as well as N-linked glycosylation sites (at amino
acid 267 and 287). No amino acid homology was found in their predicted transmembrane domains and the C
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Figure 2. TIRC7 mRNA Is Upregulated after Allostimulation of Hu-
man T Cells
(A) TIRC7 mRNA expression is upregulated in allostimulated human
T cells. MLR-0 and MLR-24 indicate time points 0 hr and 24 hr, Figure 3. Identification of the TIRC7 Protein
respectively, after coincubation of allogenic responder and stimula- (A) A single 75 kDa protein is detected by anti-TIRC7 antibodies
tor lymphocytes. (Ab79 is shown) predominantly in membrane protein extracts of
(B) TIRC7 mRNA upregulation in MLR (24 hr) is prevented by human lymphocytes. Binding of Ab79 to TIRC7 is abolished in the
Cyclosporin A (Cyc A). presence of the respective peptide P2 (Ab1P2).
(B) The same single 75 kDa protein is also detected by an anti-c-
myc antibody in membrane preparations of COS-7 cells transientlytermini. Thus, TIRC7 belongs to a larger family of struc-
transfected with a c-myc-tagged TIRC7 expression vector (COS7-t)turally related membrane proteins whose functions have
but not in untransfected COS-7 cells (COS7-nt).not been clearly elucidated.
To determine the expression kinetics of TIRC7, North-
ern blot analysis of total RNA from alloantigen-activated Northern analysis revealed that TIRC7 is almost exclu-
lymphocytes was performed. A TIRC7-specific cDNA sively expressed in immune tissues and exhibits high
probe detected the expected 2.5 kb transcript as well levels of mRNA expression in spleen, lymph nodes, pe-
as an additional 4 kb mRNA of unknown origin (Figure ripheral blood, and appendix, whereas lower levels of
2A). Alloactivation of T cells resulted in a 20-fold upregu- expression are observed in bone marrow, fetal liver, and
lation of TIRC7 expression at 24 hr (Figure 2A). TIRC7 thymus, respectively. TIRC7 was also detected in CD41
expression was transient with no increase at 1 hr, peak and CD81 lymphocytes but not in EBV-transformed pri-
expression at 24 hr, and a return to baseline at 72 hr
mary B cells, Burkitt's lymphoma cells, EBV-infected
(data not shown). To ensure that the upregulation of
Burkitt's lymphoma cells, and resting or activated JurkatTIRC7 occurred in the responder T cell population, an
cells (data not shown).additional MLR was performed using stimulators de-
In Western blot analysis, a single protein of approxi-pleted of T cells and TIRC7 mRNA expression was found
mately 75 kDa molecular mass was detected predomi-to be increased in responder T cells 24 hr after coculture
nantly in membrane extracts of human lymphocytes(data not shown).
(Figure 3A). The same protein was found in membraneCyclosporine A (Cyc A), an inhibitor of the calcineurin-
preparations from CHO cells (data not shown) and COS-7dependent T cell activation pathways, blocked the in-
cells (Figure 3B) stably and transiently transfected withduction of TIRC7 in an MLR (Figure 2B). Not shown,
a c-myc-tagged TIRC7 expression vector, respectively.exogenous high-dose IL-2 was a potent inducer of TIRC7
TIRC7 localization to the cell membrane was confirmedexpression, whereas a modest increase in TIRC7 ex-
by confocal microscopy in human lymphocytes (Figurespression was observed with Staphylococcus aureus en-
4A and 4B) as well as in stably transfected CHO cellsterotoxin B (SEB) or OKT3-MAb stimulation after 24 hr,
(data not shown). Small amounts of TIRC7 protein wasthough OKT3-MAb increased TIRC7 expression after 48
also detected in the intracellular compartment of thehr to a similar level as that induced by alloantigen. In
lymphocytes suggesting that preformed protein may ex-contrast, neither concanavalin A (ConA) nor phytohe-
ist in an endosomal compartment that is transported tomagglutinin (PHA) increased TIRC7 expression at 24 or
48 hr. the cell surface upon T cell activation.
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the TIRC7 protein (P1±P7; 12-mers) were used to pro-
duce polyclonal rabbit antipeptide antibodies (Figure
1C). As shown in Figure 5A, three of the antibodies Ab73,
Ab76, and Ab79, which were directed against the extra-
cellularly located domains, respectively, were found to
strongly inhibit the proliferation of alloactivated T cells.
In contrast, two antibodies directed against extracellular
epitopes and two antibodies recognizing intracellular
domains of TIRC7 did not exhibit immune modulatory
effects on human T cell activation. The anti-TIRC7 anti-
bodies Ab73, Ab76, and Ab79, inhibited T cell prolifera-
tion in a dose-dependent manner (data not shown). Ad-
dition of the respective TIRC7 peptides, but not peptides
unrelated to TIRC7, diminished inhibition indicating the
specific neutralization of the antibody. The antibodies
had no effect when added 24±72 hr after initiating the
MLR, suggesting that the TIRC7-mediated signal was
specific for an early event in the T cell response and
proliferation inhibition was not due to a toxic effect of
the antibodies. Moreover, no evidence for toxicity was
observed by the antibodies as examined by trypan blue
staining. The same three anti-TIRC7 antibodies also
caused efficient inhibition of T cell activation induced
by ConA, PHA, and OKT3-MAb, respectively (data not
shown).
Membrane proteins associated with T cell activation
are often involved in ligand±receptor interactions that
can be blocked by exogenous soluble protein, as has
been demonstrated by blocking of CD28/B7 interaction
with the soluble protein CTLA4Ig (Linsley et al., 1992).
In vitro±translated TIRC7 protein was therefore tested
for its ability to inhibit the MLR by adding it to MLR
cultures at time 0 (Figure 5B). Two other in vitro±trans-
lated seven-transmembrane spanning proteins, Rantes
receptor (CCR1) and Leukotriene B4 receptor, as well
as a nonmembrane protein (unpublished), served as
negative controls. Only exogenous TIRC7 protein signifi-
cantly suppressed the proliferation of alloreactive T cells
in a dose-dependent manner. In control experiments, no
inhibition was observed using other in vitro±translated
membrane or nonmembrane proteins (Figure 5B).
Targeting of the TIRC7-Mediated Signal Inhibits
Figure 4. Cellular Localization of TIRC7 Protein Type 1±Specific Cytokine Expression
Confocal microscopy shows the localization of TIRC7 protein in the To further differentiate whether signals mediated by
cell membrane (parts A and B) (yellow fluorescence) and intracellular TIRC7 differentially affect T cell subsets, human T cells
pools (part B, panels C and D; arrowheads) of human lymphocytes.
were challenged with either OKT3-MAb, ConA, or PHA,T cells were fixed (part A) and additionally permeabilized (part B).
and the cytokine profiles specific for type 1 and type 2Cells were stained for TIRC7 protein with Ab79 as shown in serial
optical sections taken at 1.5 mm (part A) and 1.9 mm (part B) intervals lymphocyte subsets were analyzed in the presence and
beginning at the surface and continuing through horizontal sections absence of anti-TIRC7 antibodies. As shown in Figure
of the T cell (parts A and B, panels A±D). No staining of TIRC7 5C, a significant decrease of the type 1±specific cyto-
protein was detected when the Ab79 was neutralized by addition kines IL-2 and IFN-g was observed at 24 hr in all cultures
of the respective peptide (not shown).
of PHA-stimulated lymphocytes. Of the three stimuli
tested, the IL-2 and IFN-g downregulation occurred in
ConA- and PHA-activated cultures at 24 hr, whereas
TIRC7 Mediates an Essential Signal during Early the OKT3-MAb-stimulated T cells showed a significant
Events of T Cell Activation decrease of IL-2 at 24 hr but of IFN-g only after 48 hr
The functional significance of a number of proteins re- (data not shown). No downregulation of IL-4 production,
quired in T cell activation has been determined by modu- which is specific for type 2 T lymphocytes, was observed
lation of their signaling by targeting with specific anti- in any of the mitogen-activated T cells after 24 and 48 hr.
bodies. To examine whether antibodies directed against Moreover, quantitative RT-PCR studies demonstrated a
TIRC7 could alter the T cell proliferative response, seven significant decrease of PHA-induced IL-2 mRNA expres-
sion after 24 hr in the presence of anti-TIRC7 antibodysynthetic peptides representing different domains of
Role of TIRC7 in Allograft Rejection
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Figure 5. Anti-TIRC7 Antibodies Inhibit T Cell
Proliferation and Type 1±Specific Cytokine
Production
In (A) and (C)±(E), control antibody 1 (control
Ab1) represents preimmune serum and con-
trol antibody 2 (control Ab2) represents Ab77,
respectively.
(A) Anti-TIRC7 antibodies (Ab73, Ab76, Ab79)
directed against extracellularly located TIRC7
peptides (P4, P6, P2) inhibit proliferation in
alloantigen-stimulated T cells as determined
by [3H]-thymidine incorporation. Inhibition
was diminished with their respective TIRC7
peptides, whereas no changes of anti-TIRC7
antibody mediated inhibition was observed
by adding TIRC7 unrelated peptides (pu) to
each of the antibodies. Proliferation in an
MLR is displayed as positive control. Prolifer-
ation was not affected by control antibody
directed against putative intracellular domain
of TIRC7 protein (Ab 77). Each bar represents
mean 6 SD from three independent experi-
ments.
(B) Inhibition of proliferation by exogenous
TIRC7 protein. In a one-way MLR in vitro±
translated TIRC7 protein inhibited prolifera-
tion in a dose-dependent manner (TIRC7-
c1 5 30 ng/ml protein; TIRC7-c2 5 50 ng/ml
protein and TIRC7-c3 5 70 ng/ml protein).
Two other seven-membrane TIRC7 unrelated
proteins, control-1 (Rantes receptor CCR1),
control-2 (Leukotriene B receptor) or control-
3 (nonreceptor protein-c7) were used as neg-
ative controls. Shown is a concentration of
70 ng/ml for all negative control experiments.
Each bar represents the mean 6 SD of three
independent experiments.
(C) Anti-TIRC7 antibodies inhibit Th1-specific
cytokine expression. PHA-stimulated human
lymphocytes were coincubated with Ab73,
Ab76, and Ab79, respectively. Supernatants
of mitogen-stimulated cultures were taken at
24 hr, and cytokine expression in the super-
natants was determined by ELISA. Each bar
represents the mean from three independent
experiments (100% 5 661 pg/ml for IL-2, 221
UI/ml for IFN-g, and 27 pg/ml for IL-4).
(D) Exogenous rIL-2 restores the diminished
T cell proliferation by antibody targeting of
TIRC7 protein. Anti-TIRC7 antibody mediated inhibition of proliferation of PHA-activated T cells that is reconstituted by exogenous rIL-2
(arrow). Each bar represents the mean 6 SD from four independent experiments.
(E) IFN-g is decreased in the PHA-activated cultures in the presence of anti-TIRC7 antibodies within the first 24 hr, and it remains decreased
when exogenous rIL-2 is added (arrow) to the culture for a second 24 hr period. Each bar represents the mean of three independent experiments.
(22.8 AU/ml cDNA in PHA-stimulated lymphocyte con- complete reversion of the inhibition was achieved when
anti-TIRC7 antibodies were present at lower concentra-trols, 33.5 AU/ml cDNA in control antibody cultures, and
4.6 AU/ml cDNA in PHA-activated lymphocytes in the tion (1:1000 dilution; data not shown).
To further analyze whether the specific inhibition ofpresence of anti-TIRC7 antibody Ab73; p , 0.01). These
results suggest that TIRC7 targeting affected T cell acti- the type 1 cytokine IFN-g was indirectly due to a lack
of IL-2 expression, human peripheral lymphocytes werevation signaling pathways involving the IL-2 mRNA ex-
pression. challenged with PHA for 24 hr in the presence of anti-
TIRC7 antibodies. rIL-2 was added 24 hr after cultureRemarkably, exogenous addition of recombinant IL-2
to mitogen-activated cultures incubated with anti-TIRC7 initiation for another 24 hr period. IFN-g concentration
was determined prior to and 24 hr after IL-2 incubation.antibodies restored, at least partially, the diminished T
cell proliferation. The restoration of T cell proliferation Although diminished T cell proliferation was partially
restored (Figure 5D), the IFN-g secretion remained con-by rIL-2 was dependent on the concentration of anti-
TIRC7 antibodies. At high concentrations (1:500 dilution) tinuously suppressed in the presence of rIL-2 for the
second 24 hr period (Figure 5E), indicating that anti-the inhibition of T cell proliferation was only partially
restored in the presence of rIL-2 (Figure 5D), whereas TIRC7 antibody mediated a stable inhibition of type 1
Immunity
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transplantation (Figure 7A). No side effects except for
transient mild diarrhea were observed in the anti-TIRC7
antibody (Ab73) treated group. Quantification of rat
CD3-, CD8-, and CD4-positive T cells flow-cytometri-
cally measured at 24 hr, day 2, and day 10 after the anti-
TIRC7 antibody treatment did not reveal a depletion of
the peripheral T cells (data not shown). Anti-TIRC7
(Ab73) antibody significantly prolonged the graft survival
time of treated animals (p , 0.001) (Figure 7A). Six of
seven allografts of the Ab73-treated animals remained
functional for more than 40 days after completion of
antibody administration. One animal treated with anti-
TIRC7 antibody (Ab73) died at day 21, three animals
around day 45, and three animals around day 80. In
contrast, all animals in control groups died of renal fail-
ure by day 7 to 9 after transplantation. Histological ex-
amination of kidney grafts from two additional Ab73-
treated animals sacrificed at day 7 posttransplantation
demonstrated very mild lymphocytic infiltration but no
signs of tissue necrosis (Figure 7B). In contrast, kidney
grafts from control animals displayed remarkable evi-
dence of acute graft rejection including diffuse mononu-
clear cell infiltrates as well as extensive areas of necrosis
(Figure 7C).
Discussion
TIRC7 represents a novel protein that plays an essential
role in T cell activation. Early after stimulation of the T
cell receptor the level of TIRC7 mRNA is transientlyFigure 6. Anti-Human TIRC7 Antibody (Ab 73) Cross-Reacts with a
increased. Upregulation of TIRC7 is also observed afterRat TIRC7 Homolog
incubation of T cells with exogenous rIL-2. The blockade(A) Anti-TIRC7 antibody (Ab) recognizes a 75 kDa protein in the
of TIRC7 mRNA upregulation is achieved with cyclo-protein lysates from rat lymphocytes, and the reaction is diminished
by addition of the appropriate peptide to the antibody (Ab1P). sporine A, indicating that TIRC7 expression is via cal-
(B) Anti-TIRC7 antibody blocks significantly the MLR from Lewis rat cineurin signaling pathway. The pattern of tissue expres-
T cells (responder) and spleen cells from Wistar Furth (stimulator) sion suggests that TIRC7 is a product of mature lymphoid
rats. Inhibition was diminished by adding the respective peptide to
cells, as TIRC7 is expressed in all lymphoid tissues withthe reaction.
low expression only in thymus, bone marrow, and fetal
liver. The TIRC7 protein is predominantly expressed on
the cell membrane, consistent with a target for an exter-response that was not exclusively due to the lack of
IL-2. Similar results were obtained when anti-TIRC7 anti- nal ligand. The seven-transmembrane domain structure
predicts three extracellular loops and an extracellularlybodies were used at lower concentration in the cultures
(data not shown). oriented carboxy terminus. Anti-TIRC7 antibodies di-
rected against the extracellular domains, but not those
recognizing predicted intracellular domains of the pro-Antibody Targeting of TIRC7 Significantly Prolongs
Renal Allograft Survival In Vivo tein, are able to efficiently suppress the proliferation of
T cells in response to alloactivation or to mitogens. TheThe effect of modulating the TIRC7-mediated signal was
studied in an animal model featuring kidney transplanta- inhibitory effect of anti-TIRC7 antibodies on T cells in-
duced by a variety of different stimuli suggests thattion from Wistar Furth to Lewis rats. In initial experi-
ments, anti-human anti-TIRC7 antibody Ab73, which TIRC7 plays a central role in T cell activation.
Interestingly, the inhibitory effect of anti-TIRC7 anti-recognized a single protein of 75 kDa in Western blot
analysis from rat lymphocyte lysates (Figure 6A), was bodies is only observed when added at the initiation of
the T cell activation process, even before TIRC7 mRNAselected for its ability to inhibit the proliferation of Lewis
rat lymphocytes stimulated with irradiated Wistar Furth upregulation occurs suggesting that the constitutively
low-level expressed TIRC7 protein on resting T cells israt lymphocytes in vitro. Ab73 was shown to profoundly
block rat T cell proliferation (Figure 6B). In kidney trans- sufficient to trigger essential processes required in early
T cell activation.plant experiments, animals either remained untreated
(n 5 7), received preimmune rabbit serum (n 5 7) or In addition, inhibition of T cell proliferation by antibody
targeting of TIRC7 may suggest the existence of a ligandanti-TIRC7 antibody recognizing a putative intracellular
domain of the TIRC7 protein (Ab 77) (n 5 7), or were specifically interacting with TIRC7. Support for this hy-
pothesis is provided by the dose-dependent inhibitiontreated with anti-TIRC7 antibody Ab73 (n 5 7), 2 hr
before, directly after, and on days 1, 2, 4, and 6 after of T cell proliferation in an MLR in the presence of in
Role of TIRC7 in Allograft Rejection
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Figure 7. Anti-TIRC7 Antibody Targeting In
Vivo Significantly Prolongs Allograft Survival
(A) Lewis rat recipients of Wistar Furth rat
kidney allografts received either anti-TIRC7
Ab73 (n 5 7), control antibody 1 (preimmune
serum) (n 5 7), control antibody 2 (recogniz-
ing an intracellular domain of human TIRC7
protein, Ab77) (n 5 7), or no treatment (n 5
7), respectively. Treatment was initiated at 2
hr prior to and immediately after transplanta-
tion, and was repeated on days 1, 2, 4, and
6 posttransplantation. Animals in control
groups showed a mean survival time of 7 6
2 days. The mean survival time in the Ab73-
treated group was 56 days (range 21±80) (p ,
0.001).
(B) Histological analysis of kidney allografts
at day 7 posttransplantation. Renal allografts
of two additional anti-TIRC7 antibody treated
animals sacrificed at day 7 showed very mild
interstitial infiltration of mononuclear cells.
Tissue lesions were not identified in the allo-
grafts of these animals.
(C) Kidney allografts of rats receiving control
antibodies (day 7) showed severe tissue de-
struction and diffuse mononuclear infiltration
that was similar to histological findings in the
kidney allografts of untreated animals.
vitro±translated TIRC7 protein. The lack of inhibition by to the putative rat H1-ATPase subunit VPP116 (Manol-
son et al., 1992). In vitro±translated J6B7 protein wasother in vitro±translated seven-membrane spanning
proteins used as controls (Rantes receptor CCR1, Leu- demonstrated to inhibit mouse T cell proliferation in an
MLR by 89%, which is comparable with the results ob-kotriene B4 receptor) indicates specificity of the inhibi-
tory effect of TIRC7 protein. tained with in vitro±translated TIRC7 protein in human
MLR in the present study.TIRC7 shares 38% amino acid homology with J6B7,
a protein isolated from a mouse T cell line (Lee et al., Antibody targeting of TIRC7 has a selective inhibitory
effect on the type 1 lymphocyte subset, as evidenced1990). Like TIRC7, J6B7 exhibits considerable homology
Immunity
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Experimental Proceduresby the inhibition of IL-2 and IFN-g, but not IL-4, cytokine
production. Although exogenous recombinant IL-2 re-
Mixed Lymphocyte Reaction and Modulationversed the antiproliferative effect of the anti-TIRC7 anti-
of T Cell Activation
bodies, suppression of IFN-g secretion was not abol- In conformance with institutional policies regarding human experi-
ished, suggesting a selective induction of a stable type mentation, peripheral blood lymphocytes (PBLs) were isolated from
healthy human volunteers using standard Ficoll centrifugation meth-1 T cell subset inhibition. These results also indicate
ods and diluted into RPMI containing 10% fetal calf serum. Re-that TIRC7 is involved in IL-2 regulation, as antibody
sponder PBLs were stimulated with equal numbers of irradiatedtargeting of TIRC7 was accompanied with substantial
(3000 rad, 13 min) stimulator PBLs. Cells were cocultured for 24 hr
decrease of IL-2 that was also demonstrated on the in tissue flasks at an initial concentration of 106 cells/ml for RNA
transcriptional level. isolation. For studies on induction or inhibition of TIRC7 expression,
Moreover, we have shown that an anti-human TIRC7 PBLs were exposed to concanavalin A (10 mg/ml), phytohemaggluti-
nin (PHA) (2 mg/ml), Staphylococcus aureus enterotoxin B (10 mg/antibody cross-reacting with a rat TIRC7 homolog was
ml), OKT3-MAb (10 mg/ml), cyclosporine A (1 mg/ml), or rIL-2 (10able to profoundly block the rat alloimmune response
U/ml). The stimulation with OKT3-MAb was carried out by immobiliz-both in vitro and in vivo. The polyclonal anti-human-
ing the antibody on plastic culture plates overnight at 48C before
TIRC7 protein derived rabbit antibody did not deplete adding the cell suspension. For RNA isolation from CD41 and CD81
peripheral T cells in rats. Confocal microscopy and flow human T cells, PBLs were incubated with immunomagnetic beads
coated with anti-CD4 or anti-CD8 IgG and then subjected to mag-cytometry experiments (not shown) demonstrated low
netic separation.density expression of TIRC7 on the surface of resting
human T cells. As antibody induced depletion of periph-
Differential Display Reverse Transcriptase±PCR Analysiseral T cells requires sufficient coating of the cells by the
Total RNA was isolated from MLR at 0 and 24 hr using the RNAzol
respective antibody, this fact might explain the lack of B method (Tel-Test, Inc.) and differential display was performed as
T cell depletion by anti-TIRC7 antibody despite constitu- described previously (Kojima et al., 1996). Briefly, 2 mg of total RNA
tive TIRC7 expression and suggests that in rats the ab- was reverse transcribed using an oligo-dT primer and 200 U MMLV
reverse transcriptase (GIBCO±BRL). A 40 cycle PCR amplificationsence of significant kidney intragraft T cell infiltration is
with a total volume of 10 ml was performed by using 1 mg of cDNA,due to prevention of T cell alloactivation as observed in
10 mM dNTPs, 1.25 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl (pHvitro.
8.3), 2.5 nM primer, 5 mCi 35S-dATP, and 0.3 U Taq polymerase. The
The effects of antibody targeting of TIRC7 are quite primers for the PCR amplification were: 59-GACGGAACAGCTTC-39
similar to those observed by targeting of costimulatory and 59-TGCGTCTGGTTCT-39. The PCR products were stored at 48C
and separated by electrophoresis in 6% polyacrylamide-urea gels,molecules. The interruption of CD28/B7 interaction with
transferred to filter paper, dried, and autoradiographed. The differ-the soluble protein CTLA4Ig or with anti-B7-1 or -B7-2
entially expressed cDNA fragment was excised from the gel, eluted,antibodies caused inhibition of T cell proliferation (Lens-
reamplifed, cloned into pBluescript SK1 plasmid, and sequenced
chow et al., 1992; Linsley et al., 1992; Sayegh et al., at the Howard Hughes Biopolymers Research Facility or the Dana
1995; Larsen et al., 1996; Blazar et al., 1996). Similar Farber Cancer Institute Biopolymer Facility at Harvard Medical
effects have been observed by blocking of CD40/CD40L School. Homology searches were performed using BLAST at NCBI.
Alignments were performed using Geneworks 2.1.1.interaction (Larsen et al., 1996). Furthermore, it was
Quantitative RT-PCR analysis for IL-2 mRNA quantitation wasshown that administration of CTLA4Ig in an in vivo model
performed by using human IL-2 control fragment (Tip Molbiol., Ber-of kidney allograft transplantation blocked the Th1 and
lin, Germany) as described by Platzer et al., 1996.
sparing Th2 cytokine response and prolonged graft sur-
vival (Sayegh et al., 1995). Although these similarities to Cloning of the Full-Length cDNA and Genomic DNA
our results may suggest a costimulatory function, TIRC7 A l-gt-10 cDNA library (Clontech) prepared from human T cells
activated for 48 hr with PHA was screened with the 350 bp TIRC7does not share structural or sequence homology with
cDNA fragment. Briefly, plaque lifts of 1,200,000 independent cDNAany of the known T cell accessory molecules. Thus,
clones were hybridized with a 32P-labeled cDNA for 24 hr at 428C inTIRC7 may participitate in a distinct signaling pathway
40% formamide, 10% dextran sulfate, 43 SSC (13 SSC consists
induced early in the course of T cell activation. This of 150 mM NaCl, 15 mM sodium citrate, pH 7.0), 0.83 Denhardt's
possibility is supported by recent reports that interfer- solution (13 Denhardt's contains of 0.02% polyvinylpyrolidone,
0.02% Ficoll, 0.02% bovine serum albumin), 0.5% sodium dodecylence with pathways mediated by molecules other than
sulfate (SDS), and 20 mg salmon sperm DNA. The filters werethe known costimulatory proteins can modulate the T
washed twice for 20 min at room temperature with 23 SSC, 10%cell response. For example, antibody targeting of the
SDS and for 30 min at 658C with 0.23 SSC, 10% SDS followed by
common leukocyte antigen CD45RB was shown to re- autoradiography. Three positive clones were selected and plaque
sult in a prevention of graft rejection in mice (Lazarovits purified. cDNA was sequenced in both directions using a primer
walking strategy. A PAC genomic library was screened using a 2et al., 1996).
kb cDNA probe containing the ORF cDNA of TIRC7, and three clonesFurther work will be needed to elucidate in detail the
representing the entire genomic cDNA of TIRC7 and OC116 werefunction of TIRC7 in T cell activation. Given the func-
bidirectionally sequenced.
tional similarities between TIRC7 and the known T cell
accessory molecules, it is likely that the structural nov- Northern Blot Analyses
elty of TIRC7 will contribute to the understanding of Northern blots were prepared with 7±10 mg of total RNA as described
previously (Kojima et al., 1996). Poly(A)1 Northern blots containingdistinct mechanisms in the T cell response. Moreover,
RNA from various human tissues were purchased from Clontech.the striking capacity of anti-TIRC7 antibody to signifi-
Northern blots were probed with the full-length TIRC7 cDNA or acantly prolong allograft survival in vivo may provide a
TIRC7-specific cDNA fragment (nt 52±391). Overnight hybridizations
novel approach for a selective inhibition of undesired were performed with 32P-labeled cDNA probes (106 cpm/ml) at 428C
T cell activation in human organ transplantation and in 40% formamide, 10% dextran sulfate, 43 SSC, 7 mM Tris (pH
7.6), 0.83 Denhardt's solution, 0.02 mg/ml salmon sperm DNA, andautoimmune diseases.
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10% SDS. Blots were washed twice in 23 SSC and 0.1% SDS for the 18 hr pulse. Peptide blocking experiments were performed by
coincubation of the antibody with the appropriate peptide for 3020 min at room temperature, once at 658C in 0.23 SSC, 0.1% SDS
and autoradiographed at 2808C. min at 48C prior to initiating the MLR. The cytokine expression for
IL-2, IL-4, and interferon-g were detected in culture supernatants
by commercial ELISA kits for IL-2 (Laboserv-/Medgenix/GermanCOS-7 and CHO Cell Transfection
provider of Biosource, Ratingen, Germany), IL-4-ultrasensitive (Lab-The full-length TIRC7 ORF was cloned upstream of a c-myc epitope
oserv), and IFN-g (Laboserv).sequence to create a fusion protein construct in a mammalian ex-
pression vector (Promega). Transient transfection of COS-7 cells
MLR Suppression by TIRC7 Proteinand stable transfection of CHO cells was performed by lipofecta-
Two micrograms of TIRC7 or control cDNAs was translated in anmine transfection method as described (SchuÈ lein et al., 1996). An
in vitro translation TNT lysate system (Promega) containing 35S-anti-c-myc antibody (InVitrogen) was used to detect the protein.
methionine (ICN). The product was visualized by SDS-page (11%)
and autoradiography. For MLR inhibition experiments the in vitroWestern Blot Analysis and Membrane Preparations
translation mixtures were suspended in 500 ml PBS and dialyzedPBLs were lysed and collected in PBS, 0.5 mM PMSF, 3.2 mg/ml
against PBS for 24 hr. For protein inhibition studies using eithertrypsine inhibitor, 1.4 mg/ml aprotinin, and 0.5 mM benzamidine.
TIRC7 protein or two TIRC7 unrelated seven transmembrane pro-Membrane preparations were obtained by centrifugation of the ly-
teins (Rantes receptor CCR1 and Leukotriene B4 receptor, kindlysates for 1 hr at 48C, 100,000 3 g, twice. Lysates were separated
provided by A.D. Luster), or a TIRC7 unrelated nonmembrane proteinby SDS-PAGE and transferred to a nitrocellulose membrane. Filters
(not published) in a concentration of 70 (c1), 50 (c2), and 30 (c3) ng/were blocked for 1 hr with Blotto (20 mM Tris±HCl [pH 7.5], 0.15
ml, respectively, of the dialyzed in vitro±translated proteins weremM NaCl, 5% dried milk powder, 1% Triton X-100). Anti-TIRC7
added to MLRs. Inhibition was measured by 3H-thymidine incorpo-antibodies were added (dilution 1:200) and incubated for 2 hr at
ration.room temperature. For peptide blockade experiments peptides were
used in 1:200 dilutions and incubated with the respective antibody
Renal Transplantation and Histology of Kidney Allograftsfor 30 min at 48C. Filters were then washed four times (15 min
Male inbred rats 200±250 g (Harlan Winkelmann, Germany) wereeach) with Blotto and then incubated with alkaline phosphatase
used throughout the experiment. Wistar Furth rats (WF, RT1u) wereconjugated anti-rabbit IgG (1:4000 in Blotto) for 1 hr at room temper-
grafted into bilaterally nephrectomized Lewis rats (LEW, RT11) usingature. Filters were then washed four times with Blotto (10 min each),
microsurgical techniques; ischemic time was 30 6 5 min. Anti-TIRC7two times with Blotto without dried milk powder (10 min each), and
Ab73 and the control antibodies (preimmune serum, and Ab77) wereonce for 5 min with 10 mM Tris±HCl (pH 9.5). Filters were incubated
injected 6 times at a dose of 0.5 ml/injection.with staining solution (0.56 mM BCIP, 0.48 mM MBT in 10 mM
Cryostat sections were fixed in formalin. The fixed tissue wasTris±HCl [pH 9.5]) until bands became visible. Specificity of antibody
paraffin embedded, and tissue sections were stained with hematox-binding was proofed by blocking with 200-fold excess of the respec-
ylin and eosin.tive peptide.
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